All News

Mark D. Tyson II, MD, MPH, discusses findings from the phse 3b PATAPSCO study, evaluating durvalumab plus BCG for patients with BCG-naïve, high-risk NMIBC.

Interim results from the pivotal Expander-2 showed sustained symptom improvement through 24 months with the Urocross Expander system for BPH.

Mark Garzotto, MD, discusses phase 3 data on aglatimagene besadenovec plus standard-of-care external beam radiation therapy with or without short-course androgen deprivation therapy in localized prostate cancer.

Bashir Al Hussein Al Awamlh, MD, MPH, discusses findings from an international registry study evaluating how baseline sexual interest may influence sexual bother outcomes after treatment for localized prostate cancer.

Sarah P. Psutka, MD, MSc, reflects on her AUA 2026 talk regarding frailty and surgical outcomes in urologic oncology.

Vesta Bladder Risk Stratify Dx applies AI foundation models to H&E pathology slides obtained during routine clinical care to generate prognostic risk assessments.

The agency issued a PDUFA target action date of January 6, 2027.

Rana R. McKay, MD, FASCO, shares results from the ARASEC study, which evaluated darolutamide plus ADT in mHSPC using a novel external control-arm design.

The lower bound of the 95% CI (57.6%) exceeded the prespecified noninferiority effectiveness performance goal of 50.9%, thereby meeting the primary effectiveness end point.

The INTIBIA Pivotal Study—the first sham-controlled, double-blind RCT of an implantable tibial nerve stimulation device—demonstrated significantly greater clinically meaningful improvements in symptom bother, health-related quality of life, and patient global impression at 3 months compared with sham, with durable benefits through 12 months.

Chad A. Reichard, MD, highlights real-world data presented at AUA 2026 on re-induction with nadofaragene firadenovec in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

Extended follow-up data from a phase 3 randomized trial show that aglatimagene besadenovec plus valacyclovir combined with radiotherapy produced a 39% improvement in prostate cancer-specific disease-free survival vs placebo plus standard-of-care radiotherapy in men with intermediate- to high-risk localized prostate cancer.

Adam B. Weiner, MD, is joined by Mary Beth Westerman, MD, FACS, to discuss the landmark CISTO trial—a large pragmatic study examining patient-reported outcomes among individuals with high-risk non–muscle invasive bladder cancer who underwent either bladder-sparing therapy or radical cystectomy.

"I think these data clearly support one year of durvalumab in combination with induction maintenance BCG as a potential new treatment for patients with BCG high-risk NMIBC with the appropriate shared decision-making conversation," said Neal D. Shore, MD, FACS.

Darolutamide plus ADT also significantly delayed time to mCRPC (HR 0.26; 95% CI 0.18–0.38; P <.001) and rPFS (HR 0.30; 95% CI 0.19–0.48; P <.001) vs ADT.

The agency simultaneously approved the Signatera CDx as a companion diagnostic to identify patients with ctDNA MRD who are eligible for treatment.

In this episode of Pearls & Perspectives, Amy Pearlman speaks with Heather Florio about the evolving role of evidence-based nutraceuticals and nonhormonal therapies in managing interstitial cystitis, chronic pelvic pain, recurrent urinary symptoms, and menopausal bladder health.

A comprehensive guide to the practice-changing, paradigm-shifting studies across benign urologic conditions.

With this expansion, the platform now represents a comprehensive automated testosterone testing solution.

Krishnan discusses how prolapse stage, patient lifestyle, and nuanced mesh counseling inform individualized decision-making around robotic sacrocolpopexy vs vaginal reconstructive repair.

A comprehensive guide to the practice-changing, paradigm-shifting studies across urologic oncology.

The 2026 AUA Annual Meeting will feature significant bladder cancer data, a plenary lecture on screening and overdetection, and programming that integrates advanced practice providers across sessions, against a backdrop of AUA-driven policy wins including removal of the vaginal estrogen black box warning and early steps toward a federal Office of Men's Health.

Isaac Y. Kim, MD, PhD, MBA, reflects on concerning trends in prostate cancer mortality, emphasizing how advances in diagnostics, treatment, and artificial intelligence may improve outcomes in the future.

Yeonsoo Sara Lee, MD, highlights the key networking and education opportunities she's most looking forward to at AUA 2026.

HistoSonics has submitted a de novo request to the FDA seeking an expanded indication for its Edison Histotripsy System.